---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039047"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:21:47.155931+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q2 2023 cash $157.1M, initiates BDC-1001 Phase 2, gets IND for BDC-3042

## Summary
- Cash, equivalents and marketable securities $157.1M as of June 30, 2023; runway expected through 2025.
- First patients dosed in BDC-1001 Phase 2 dose-expansion study for HER2+ colorectal, endometrial, and gastroesophageal cancers.
- FDA cleared IND for BDC-3042 (Dectin-2 agonist) in July 2023; Phase 1 start expected later in 2023.
- Loss from operations $19.8M in Q2 2023 vs $23.1M in Q2 2022; R&D expenses reduced to $15.6M from $18.9M.
- Collaboration revenue flat at $1.4M; G&A essentially unchanged at $5.6M.

## SEC filing metadata
- accession: 0000950170-23-039047
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017023039047/0000950170-23-039047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017023039047/bolt-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039047
- JSON: https://secwatch.observer/filing/0000950170-23-039047.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.